The glycosylation-oriented engineering of human vasopressin

doi:10.5246/jcps.2017.09.072

Abstract

CLC Number:

R916

Supporting: 1. Peptide 19

Figure S1. HPLC trace and ESI-MS data of peptide 19. Linear gradient: 10%–30% solvent B over 30 min, Agilent C₁₈ column, t_R = 19 min; Calcd for C₄₆H₆₇N₁₅O₁₂S₂: 1086.26 Da (average isotopes), [M+1H]⁺ m/z = 1087.26, [M+2H]²⁺ m/z = 544.13; observed [M+H]⁺ m/z = 1086.43, [M+2H]²⁺ m/z = 544.02.

2. Glycopeptide 20

Figure S2. HPLC trace and ESI-MS data of peptide 20. Linear gradient: 10%–30% solvent B over 30 min, Agilent C₁₈ column, t_R = 19.3 min; Calcd for C₅₈H₈₇N₁₇O₁₉S₂: 1390.55 Da (average isotopes), [M+1H]⁺ m/z = 1391.55, [M+2H]²⁺ m/z = 696.28; observed: [M+1H]⁺ m/z = 1390.55, 1187.47^*, [M+2H]²⁺ m/z = 696.20, 594.61^*. ^*Signals denote the GlcNAc-cleaved species during ionization in mass spectrometry.

3. Glycopeptide 21

Figure S3. HPLC trace and ESI-MS data of peptide 21. Linear gradient: 10%–30% solvent B over 30 min, Agilent C₁₈ column, t_R = 17.9 min; Calcd for C₅₄H₈₀N₁₆O₁₇S₂: 1289.45 Da (average isotopes), [M+1H]⁺ m/z = 1290.45, [M+2H]²⁺ m/z = 645.72; observed: [M+1H]⁺ m/z = 1289.55, [M+2H]²⁺ m/z = 645.52. ^#Peak denotes the oxidized species (3) after storage for several days.

4. Glycopeptide 22

Figure S4. HPLC trace and ESI-MS data of peptide 22. Linear gradient: 10%–30% solvent B over 30 min, Agilent C₁₈ column, t_R = 17.5 min; Calcd for C₅₄H₈₀N₁₆O₁₇S₂: 1289.45 Da (average isotopes), [M+1H]⁺ m/z = 1290.45, [M+2H]²⁺ m/z = 645.72; observed: [M+1H]⁺ m/z = 1289.61, [M+2H]²⁺ m/z = 645.58.

5. Cyclopeptide 1

Figure S5. HPLC trace and ESI-MS data of peptide 1. Linear gradient: 10%–30% solvent B over 30 min, Agilent C₁₈ column, t_R = 19.2 min; Calcd for C₄₆H₆₅N₁₅O₁₂S₂: 1084.24 Da (average isotopes), [M+1H]⁺ m/z = 1085.24, [M+2H]²⁺ m/z = 543.12; observed: [M+1H]⁺ m/z = 1084.41, [M+2H]²⁺ m/z = 543.08.

6. Glycopeptide 2

Figure S6. HPLC trace and ESI-MS data of peptide 2. Linear gradient: 10%–30% solvent B over 30 min, Agilent C₁₈ column, t_R = 18.7 min; Calcd for C₅₈H₈₅N₁₇O₁₉S₂: 1388.54 Da (average isotopes), [M+1H]⁺ m/z = 1389.54, [M+2H]²⁺ m/z = 695.27; observed: m/z = 1388.69, 1185.59^*, [M+2H]²⁺ m/z = 695.08, 593.51^*. ^*Signals denote the GlcNAc-cleaved species during ionization in mass spectrometry.

7. Glycopeptide 3

Figure S7. HPLC trace and ESI-MS data of peptide 3. Linear gradient: 10%–30% solvent B over 30 min, Agilent C18 column, t_R = 16.8 min; Calcd for C₅₄H₇₈N₁₆O₁₇S₂: 1287.43 Da (average isotopes), [M+1H]⁺ m/z = 1288.43, [M+2H]²⁺ m/z = 644.72; observed: [M+1H]⁺ m/z = 1287.50, [M+2H]²⁺ m/z = 644.59.

8. Glycopeptide 4

Figure S8. HPLC trace and ESI-MS data of peptide 4. Linear gradient: 10%–30% solvent B over 30 min, Agilent C₁₈ column, t_R = 17.2 min; Calcd for C₅₄H₇₈N₁₆O₁₇S₂: 1287.43 Da (average isotopes), [M+1H]⁺ m/z = 1288.43, [M+2H]²⁺ m/z = 644.72; observed: [M+1H]⁺ m/z = 1287.50, [M+2H]²⁺ m/z = 644.53.

Hongxing Li, Ning Yuan, Suwei Dong. The glycosylation-oriented engineering of human vasopressin[J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(9): 642-649.

References

[1] Kounin, G.; Bashir, Q. Surg. Neurol. 2000, 53, 508–510.

[2] Treschan, T.A.; Peters, J. J. Am. Soc. Anesthesiol. 2006, 105, 599–612.

[3] Holt, N.F.; Haspel, K.L. J. Cardiothorac. Vasc. Anesth. 2010, 24, 330–347.

[4] Robinson, A.G. N. Engl. J. Med. 1976, 294, 507–511.

[5] Richardson, D.W. Ann. Intern. Med. 1985, 103, 228.

[6] Pesaturo, A.B.; Jennings, H.R.; Voils, S.A. Ann. Pharmacother. 2006, 40, 2170–2177.

[7] Uriz, J.; Ginès, P.; Cárdenas, A.; Sort, P.; Jiménez, W.; Salmerón, J.M.; Bataller, R.; Mas, A.; Navasa, M.; Arroyo, V.; Rodés, J. J. Hepatol. 2000, 33, 43–48.

[8] Elliott, S.; Lorenzini, T.; Asher, S.; Aoki, K.; Brankow, D.; Buck, L.; Busse, L.; Chang, D.; Fuller, J.; Grant, J.; Hernday, N.; Hokum, M.; Hu, S.; Knudten, A.; Levin, N.; Komorowski, R.; Martin, F.; Navarro, R.; Osslund, T.; Rogers, G.; Rogers, N.; Trail, G.; Egrie, J. Nat. Biotechnol. 2003, 21, 414–421.

[9] Walsh, G.; Jefferis, R. Nat. Biotechnol. 2006, 24, 1241–1252.

[10] Moradi, S.V.; Hussein, W.M.; Varamini, P.; Simerska, P.; Toth, I. Chem. Sci. 2016, 7, 2492–2500.

[11] Hu, H.; Xue, J.; Swarts, B. M.; Wang, Q.; Wu, Q.; Guo, Z. J. Med. Chem. 2009, 52, 2052–2059.

[12] Zou, Y.; Zhao, Q.; Zhang, C.; Wang, L.; Li, W.; Li, X.; Wu, Q.; Hu, H. J. Pept. Sci. 2015, 21, 586–592.

[13] Zhao, Q.; Zou, Y.; Guo, J.; Yu, S.; Chai, X.; Hu, H.; Wu, Q. Tetrahedron. 2014, 70, 7780–7787.

[14] Kihlberg, J.; Aahman, J.; Walse, B.; Drakenberg, T.; Nilsson, A.; Soederberg-Ahlm, C.; Bengtsson, B.; Olsson, H. J. Med. Chem. 1995, 38, 161–169.

[15] Suzuki, K.; Susaki, H.; Okuno, S.; Yamada, H.; Watanabe, H.K.; Sugiyama, Y. J. Pharmacol. Exp. Ther. 1999, 288, 888–897.

[16] Susaki, H.; Suzuki, K.; Yamada, H.; Okuno, S.; Watanabe, H.K. Biol. Pharm. Bull. 1999, 22, 1094–1098.

[17] Peter-Katalinić, J. Methods. Enzymol. 2005, 139–171.

[18] Schwarz, F.; Aebi, M. Curr. Opin. Struct. Biol. 2011, 21, 576–582.

[19] Lannoo, N.; Van Damme, E.J.M. Plant Sci. 2015, 239, 67–83.

[20] Dullenkopf, W.; Castro-Palomino, J.C.; Manzoni, L.; Schmidt, R.R. Carbohydr. Res. 1996, 296, 135–147.

[21] Graham, M.E.; Stone, R.S.; Robinson, P.J.; Payne, R.J. Org. Biomol. Chem. 2012, 10, 2545.

[22] Premdjee, B.; Adams, A. L.; Macmillan, D. Bioorg. Med. Chem. Lett. 2011, 21, 4973–4975.

[23] Cao, Z.; Qu, Y.; Zhou, J.; Liu, W.; Yao, G. J. Carbohydr. Chem. 2015, 34, 28–40.

[24] Zhang, Y.; Muthana, S. M.; Farnsworth, D.; Ludek, O.; Adams, K.; Barchi, J.J.; Gildersleeve, J.C. J. Am. Chem. Soc. 2012, 134, 6316–6325.
[25] Kajihara, Y.; Tanabe, Y.; Sasaoka, S.; Okamoto, R. Chem. Eur. J. 2012, 18, 5944–5953.